SEC Form 4 · accession 0001209191-15-068183
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Aug 26, 2015
Accepted (ET)
Aug 27, 2015 · 3:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 26, 2015 | M | 10,400 | $35.64 | A | 355,684 | D | |
| Common StockF2,F3 | Aug 26, 2015 | S | 900 | $122.09 | D | 354,784 | D | |
| Common StockF2,F4 | Aug 26, 2015 | S | 4,082 | $123.09 | D | 350,702 | D | |
| Common StockF2,F5 | Aug 26, 2015 | S | 600 | $124.44 | D | 350,102 | D | |
| Common StockF2,F6 | Aug 26, 2015 | S | 2,000 | $125.15 | D | 348,102 | D | |
| Common StockF2,F7 | Aug 26, 2015 | S | 1,200 | $126.21 | D | 346,902 | D | |
| Common StockF2,F8 | Aug 26, 2015 | S | 200 | $126.95 | D | 346,702 | D | |
| Common StockF2,F9 | Aug 26, 2015 | S | 900 | $128.67 | D | 345,802 | D | |
| Common StockF2,F10 | Aug 26, 2015 | S | 518 | $129.51 | D | 345,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common Stock | holding | — | — | — | 122,700 | I | Common Stock held in trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F11 | $35.64 | Aug 26, 2015 | M | 10,400 | D | — | Feb 1, 2016 | Common Stock | 10,400 | 229,600 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F10Open market sales reported on this line occurred at a weighted average price of $129.51 (range $129.25 to $129.85).
- F11Fully vested.
- F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $122.09 (range $121.81 to $122.71).
- F4Open market sales reported on this line occurred at a weighted average price of $123.09 (range $122.82 to $123.71).
- F5Open market sales reported on this line occurred at a weighted average price of $124.44 (range $123.84 to $124.75).
- F6Open market sales reported on this line occurred at a weighted average price of $125.15 (range $124.88 to $125.76).
- F7Open market sales reported on this line occurred at a weighted average price of $126.21 (range $125.88 to $126.66).
- F8Open market sales reported on this line occurred at a weighted average price of $126.95 (range $126.95 to $126.95).
- F9Open market sales reported on this line occurred at a weighted average price of $128.67 (range $128.03 to $128.93).